Drug Approval | February 21, 2023
Astellas updates on Fezolinetant application in US
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
The new sterile filling line meets cGMP aseptic filling regulatory requirements
Cipla has received 8 inspectional observations in Form 483
Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States
Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability
With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC
The workshop strived to sensitize states and various stakeholder departments regarding their role in the implementation of National Patient Safety Implementation Framework, as well as augment capacity building of health care professionals
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
Themis will market this drug with the brand name REMITHEM.
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
Subscribe To Our Newsletter & Stay Updated
